Skip to main content

Table 6 Base-case cost and effectiveness results of treatment strategies (per patient)

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

Discounted (3% annual discount rate)
Second-line agent add-on to Metformin Total Incremental
Costs LYs gained Costs LYs gained ICER
Sulfonylurea $7004 11.81    
Dipeptidyl peptidase-4 inhibitor $18853 12.42 $11849 0.61 $19420
Undiscounted
Sulfonylurea $10501 15.68    
Dipeptidyl peptidase-4 inhibitor $28013 16.70 $17512 1.02 $17170
  1. All costs were expressed in 2015 US dollars ($)
  2. Acronyms: LY-Life-year, CER-cost-effectiveness ratio (equal to cost/LY), ICER- incremental cost-effectiveness ratio (equal to incremental cost/incremental LYs)